28-Jan-2019 By Ben Hargreaves
Novartis joined industry associations in expressing concerns over the impact that a ‘hard’ or ‘disorderly’ Brexit could have on the life sciences sector.
15-Aug-2017 By Melissa Fassbender
Thermo Fisher Scientific has announced offerings of common stock after extending its tender offer to purchase Patheon.
23-Feb-2017 By Melissa Fassbender
QuintilesIMS has announced an offering of senior notes and a proposed debt refinancing as leadership looks to drive revenue growth, according to a Jefferies analyst.
14-Jul-2016 By Melissa Fassbender
Bayer has continued talks with agri-giant Monsanto over the past several weeks, upping its previous offer to the company.
12-Jul-2016 By Gareth Macdonald
Patheon NV has launched its IPO a year after announcing its intention to go public.
13-Jul-2015 By Zachary Brennan
China-based CDMO (contract development and manufacturing organization) WuXi PharmaTech has raised about $80m for subsidiary SynTheAll Pharmaceutical Co. (STA) via the private placement of 7.16m common shares of STA stock.
15-May-2015 By Zachary Brennan
Quintiles has completed its previously announced refinancing in which it entered into new senior secured credit facilities totaling $1.95bn, consisting of a $500m revolving credit facility and $1.45bn of term loans.
21-Apr-2015 By Dan Stanton
A merger with Mylan would “transform the global generics space” says Teva, which has entered a $40bn bid as an alternative to the recently proposed Mylan-Perrigo deal.
06-Apr-2015 By Zachary Brennan
Chinese service provider WuXi PharmaTech has sold a 5.55% stake in its wholly owned CMO (contract manufacturing organization) subsidiary SynTheAll Pharmaceutical (STA) to members of STA’s and WuXi’s management for $28m.
26-Feb-2015 By Zachary Brennan
Between May 2013, when Quintiles went public, and this week, newly public companies’ stocks in the biopharma outsourcing space have all seen their prices rise by more than 35%.
24-Feb-2015 By Gareth Macdonald
Catalent wants to raise $629.3m (EUR550m) through a follow-on offering that will see Blackstone sell 17.6m shares.
16-Oct-2014 By Dan Stanton
AbbVie’s proposed £31bn ($50bn) takeover of Shire is very likely “dead” after the US biopharma's board changed its recommendation and advised shareholders not to back the bid.
18-Mar-2014 By Dan Stanton
The Board of Directors at Indian firm Orchid has approved the sale of its API business to Hospira, bringing the acquisition a step closer to completion.
Jubilant Life Sciences has dismissed claims it is looking to sell off its fine chemicals business.
16-Dec-2013 By Gareth Macdonald
Elder Pharmaceuticals has agreed to sell its branded drug portfolio to Torrent Pharmaceuticals in a deal that will refocus the firm as a CMO and anti-infectives producer.
Drug ingredient supplier Shasun Pharmaceuticals has announced its intention to sell its API plant in Vizag, India.
17-Jul-2013 By Dan Stanton
Analysts from rating agency Moody's have upgraded their view of Quintiles, the world’s “largest pharmaceutical service provider,” from stable to positive.
Operations have restarted at one of Shasun’s API facilities in India following a strike last month.
30-Apr-2013 By Zachary Brennan
CRO Quintiles and its shareholders are offering more than 19 million shares of common stock that will be priced between $36 and $40 per share, according to an updated S-1 filing with the US SEC.
28-Jun-2012 By Natalie Morrison
It seems service quality really does mean bigger profits for CROs serving the pharma and biopharma industries, according to Industry Standard Research’s (ISR) new report.
09-Jan-2012 By Gareth Macdonald
Albany Molecular Research (AMRI) says ‘streamlining’ plan will focus on its drug licensing unit not its contract API research, development and manufacturing services division.
Breaking news from PPD whose CEO Raymond Hill has departed – People on the move
14-Dec-2011 By Natalie Morrison
Outsourcing-Pharma presents its latest round-up of the comings and goings in the pharmaceutical sector, with breaking news from PPD whose CEO Raymond Hill has departed.
Asterand seeking funds after share slash
05-Sep-2011 By Natalie Morrison
Asterand says it must raise additional funds after share prices dropped by more than half last week.
SeraCare Life Sciences say they are prepared to sell
04-Aug-2011 By Natalie Morrison
Contract services firm SeraCare Life Sciences are considering a sale in what it says is part of a major shake-up to drive shareholder value.
BASF posts Q2 gains, but share price falls on lacklustre guidance
BASF posts Q2 results and says economic uncertainties mean industrial customers are still cautious about placing orders.
UBC/ Bracket tight-lipped over ExpressScript-Medco merger
Express Script will take over fellow PBM Medco after a definitive merger agreement was unanimously approved by the boards of directors of both companies.
Clariant acquires Süd Chemie
28-Apr-2011 By Pooja Kondhia
Switzerland – based specialty chemicals group Clariant has acquired 96.15 per cent of German Süd – Chemie.
Spencer’s board happy with buyout
Spencer Pharmaceutical’s board of directors in favour of $0.97 per share buyout offer from anonymous buyer.
BioClinica shareholder calls for managment resignations
04-Oct-2010 By Alexandria Pesic
BioClinica shareholder Nicusa Capital is calling for the resignation of CEO Mark Weinstein, CFO Ted Kaminer and Chairman David Nowiki, after describing the firm’s corporate strategy as “defective.”
Covance adds 40,000 sq ft US biotech services laboratory
30-Sep-2010 By Nick Taylor
Covance has added a 40,000 sq ft biotech laboratory to its site in Indiana, US site to support its relationship with Eli Lilly and boost capacity outside Europe.
Biovail and Valeant to merge
Canada’s Biovail plans to buy Valeant Pharmaceuticals to strengthen US position in specialty CNS, dermatology and generics markets.
Piramal eyes CRO acquisitions
Piramal Healthcare is planning to raise Rs 10bn ($218m) over the next six to eight months to fund overseas acquisitions, with the India-based company eying several sectors including contract research.
Deltagen adds to discovery offering with Benten buy
15-Dec-2009 By Charlotte LoBuono
US drug discovery group Deltagen has acquired Benten BioServices, a contract services organisation that offers a suite of regulatory-compliant manufacturing and testing services to support biopharmaceutical development and commercialisation.
LSR goes private in Lion Holdings takeover
US CRO Life Science Research has become a private company with the completion of its acquisition by Lion Holdings, an investment vehicle owner by CEO Andrew Baker.
Patheon & JLL enter into litigation settlement
01-Dec-2009 By Nick Taylor
Patheon and JLL are to end the legal actions between them by entering into a litigation settlement which establishes a board of directors and limits JLL acquiring additional restricted voting shares before April 27 2012.
JLL says Lonza’s $460m Patheon bid is “hostile”
04-Sep-2009 By Gareth Macdonald
US investment group JLL has described Lonza’s rival offer for Patheon as “a hostile attempt to adversely impact [the Canadian contractor’s] competitive position.”
Genzyme hit with $8bn lawsuit
30-Jul-2009 By Nick Taylor
Shareholders have filed an $8bn (€5.7bn) lawsuit against Genzyme alleging that the company’s CEO “issued a series of materially false and misleading statements” about its manufacturing problems.
JLL bid “irrelevant”, says Patheon after win in Canadian Courts
29-Jul-2009 By Gareth Macdonald
In the latest twist in an increasing bitter takeover battle, the Ontario Superior Court of Justice has rejected JLL’s bid to oust directors elected to the board of Canadian CMO Patheon in April.
PharmaNet now private as JLL deal goes through
02-Apr-2009 By Phil Taylor
Top 10 contract research organization (CRO) PharmaNet has gone into private hands following the conclusion of its acquisition by private equity firm JLL Partners.
Patheon seeks legal advice on JLL hostile bid
30-Mar-2009 By Phil Taylor
The committee set up by Patheon to review the unsolicited bid by private equity firm JLL to take control of the firm has asked for advice on the legality of the move.
Roche raises Genentech bid to $45.7bn
09-Mar-2009 By Nick Taylor
Roche has upped its offer for Genentech to $93 a share, believing that this will be sufficient to bring the drawn out takeover to a close.
Under pressure MDS may sell off divisions
09-Feb-2009 By Nick Taylor
MDS has formed a special committee to improve shareholder value following poor results and pressure from investors to sell some of its business units, which include a CRO division.
Poor API sales send Perrigo stock tumbling
04-Feb-2009 By Nick Taylor
Falling API sales and “an unprecedented negative economic environment” have forced Perrigo to cut its fiscal 2009 profit forecast and sent stock plummeting by 20 per cent.
PharmaNet finds private equity buyer
04-Feb-2009 By Phil Taylor
Contract research organisation PharmaNet Development Group has found a buyer just a few weeks after saying it was considering placing itself on the block.
Takeover bid as Patheon returns to profit in Q4
16-Dec-2008 By Phil Taylor
Contract development and manufacturing company Patheon received an unsolicited takeover bid from private equity firm JLL Partners ahead of reporting a return to profit in its fiscal fourth quarter results.
Departure debacle: Hermelin and KV part company
08-Dec-2008 By Gareth Macdonald
KV Pharmaceuticals’ long-serving CEO Marc Hermelin has either been sacked or has retired, depending on which party’s version of events one believes, and is being replaced by David Vliet CEO of the company’s Ethex division on an interim basis.
Economic turmoil hits Chesapeake
08-Oct-2008 By Nick Taylor
Packaging firm Chesapeake has become a visible casualty of the current economic climate, with the New York Stock Exchange (NYSE) suspending trading of its shares.
Troubled Encorium mounts defense of shares
08-Oct-2008 By Phil Taylor
Contract research organisation Encorium has bought $250,000 of its own stock in a bid to stabilise its share price, which has been in steep decline in recent weeks.
Ranbaxy claims big pharma company behind falsification accusations
17-Jul-2008 By Nick Taylor
Ranbaxy has claimed that a pharmaceutical company is making a
concerted effort to depress the company's share price by initiating
the accusations that the generics manufacturer falsified data to
PDL restructures to recover
04-Jun-2008 By Nick Taylor
PDL Biopharma has restructured its board of directors and
reaffirmed its strategic focus as it attempts to recover from a